This article was originally published in The Gray Sheet
Redmond, Washington-based developer of the Metrix 3000 implantable atrial defibrillator announces that Invemed Associates, underwriters for its initial public offering, has exercised its over-allotment option to purchase $2.8 mil. in shares of common stock. Including the over-allotment, net proceeds from the offering, which was announced in July ("The Gray Sheet" July 18, p. 9), will be about $30.3 mil. Proceeds from the offering are pegged to fund research and development, clinical trials, and to establish European operations
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.